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ABSTRACT
Objective: The objective of this study is to compare the mucopenetration ability of metronidazole loaded chitosan (CS) and pegylated CS nanoparticles.
Methods: Nanoparticles were prepared by ionic gelation technique using negatively charged pH sensitive polymer, hydroxyl propyl methyl cellulose 
phthalate with positively charged CS and methoxy polyethylene glycol-grafted-CS (mPEG-g-CS). mPEG-g-CS was synthesized by formaldehyde linkage 
method and characterized by Fourier transform infrared spectroscopy. The optimized formulations were compared for morphology, particle size, 
polydispersity index (PDI), entrapment efficiency, bioadhesion detachment force, in vitro and in vivo mucopenetration for CS-mPEG-g-CS nanoparticles.
Results: The morphological assessment revealed smooth spherical particles with uniform dispersions. The optimized formulations particle size was 
found to be 202.7±27 nm and 294.1±46 nm, zeta potential 26.94±2.4 mV and 6.0±1.3 mV. PDI 0.231 and 0.268, entrapment efficiency 79.8±5.4% and 
83.6±9.7%, bio-adhesion detachment force 14.98*103 dyne/cm2 and 10.67*103 dynes/cm2, in vitro mucopenetration 78% and 98% for CS-mPEG-g-CS, 
respectively. The qualitative in vivo mucopenetration result confirms retention of fluorescein isothiocyanate (FITC) labeled mPEG-g-CS nanoparticles 
till 24 hrs.
Conclusion: Nanoparticles with lesser zeta potential and mucoadhesion showed higher mucosal penetration which is evident from FITC labeled 
histopathological mucus penetration test. Studies thus provided evidence that planned pharmaceutical strategies open new vistas for effective 
treatment of mucosal infections.
Keywords: Chitosan, Methoxy polyethylene glycol-grafted-chitosan, Nanoparticles, Hydroxyl propyl methyl cellulose phthalate, Ionic gelation, 
Mucopenetration.
INTRODUCTION
Amoebiasis is a chronic disorder of intestinal mucosa with organ 
susceptibility to the colon. The conventional delivery systems used 
to treat the disease are not able to provide the drug in required 
concentration at target site [1]. Metronidazole is a preferred drug in 
the treatment of amoebiasis, giradiasis, trichomoniasis and anaerobic 
infections. The drug is to be delivered to the colon for its effective action 
against trophozoites of Entoamoeba histolytica and Giradia lamblia 
where the respective trophozoites reside in lumen of the caecum and 
large intestine and adhere to colonic mucus and epithelial layers. 
However, pharmacokinetic profile of metronidazole indicates that drug 
is completely absorbed in approximately 1 hr after oral administration. 
The administration of this drug in conventional tablet dosage forms 
provides a minimal amount of metronidazole for local action in the 
colon with unwanted systemic side effects [2]. The various strategies 
used in the literature for colon targeting through oral route include 
prodrugs, enzymatic activity of colonic microflora, higher pH, colonic 
pressure and transit time [3]. In addition to it, overall dimensions of the 
delivery system are significantly affecting the inflamed colon targeting. 
Nanosized particles are more effective as a delivery system for mucosal 
delivery due to their size and ability to protect the drug at inter and 
intracellular level. However, their limited permeability to mucus layer 
prevents the drug to reach the underlying cells.
Mucus is a viscoelastic, adhesive hydrogel protective covering of 
gastrointestinal tract, lungs, and female reproductive system. The 
thickness of intestinal mucus is 100-180 nm, and it is composed of 
glycoproteins, lipids, electrolytes, cells, and cell debris [4]. The main 
role of mucus is to entrap foreign particles efficiently and remove them 
rapidly. The viscoelasticity and adhesive property of mucus retards 
nanoparticles diffusion in the mucus. Thus, surface modification of 
nanoparticles with polyethylene glycol (PEG) could help in reducing 
interaction by creating hydrophilic surface between mucus and delivery 
system, thus enabling unrestricted diffusion through the disturbed 
epithelium [5,6]. PEG is a hydrophilic and uncharged synthetic polymer, 
having many advantages as prolonged residence time in the body 
since it is not recognized by reticuloendothelial system and decreased 
degradation by enzymes when combined with the drug. It increases 
particle translocation through the mucus as well as mucosa. This 
hydrophilic surface provides an accelerated translocation into the leaky 
inflamed intestinal epithelium, which is ideal for colitis targeted drug 
delivery [7].
Chitosan (CS) is a cationic polysaccharide composed of randomly 
distributed - (1-4)-linked d-glucosamine (deacetylated unit) and 
N-acetyl-d-glucosamine (acetylated unit). It is used to prepare 
nanoparticles as it opens tight junctions between epithelial cells, leading 
to an increase in paracellular permeability. It is water soluble and bio-
adhesive that readily attaches to negatively charge surface of mucus 
membrane [8]. Furthermore, CS has plenty of hydroxyl and amino 
groups which facilitate nanoparticles formulation through physical and 
chemical cross-linking [9], biodegradability [10], antimicrobial activity, 
good homeostatic properties, and anti-cancerous properties [11] 
further make this polymer an ideal choice for the formulation of 
nanoparticles. The main limitation of CS nanoparticles for oral delivery 
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is the easy dissolution of the polymer matrix in the pH of the stomach 
by protonation of the amino groups at low pH values. As the polymer 
matrix gets dissolved, the entrapped drug is rapidly released in the 
stomach [12]. Hence, to protect the drug from stomach ionic gelation of 
CS was done with hydroxyl propyl methyl cellulose phthalate (HPMCP). 
The pKa of the free carboxylic groups of HPMCP is approximately 5.2. 
This free carboxylic acid becomes negatively charged at higher pH 
values and represents the driving force for the electrostatic interaction 
with CS.
The aim of the present study was to develop mucus penetrating, 
acid stable formulation of CS and methoxy PEG-grafted-CS (mPEG-
g-CS) nanoparticles for local delivery of metronidazole to colonic 
tissue by oral administration. The nanoparticles were prepared by 
ionic interaction of CS and mPEG-g-CS6 with HPMCP. The prepared 
nanoparticles were then evaluated for particle size, shape, surface 
charge, polydispersity index (PDI), drug loading, in vitro, ex vivo 
release and bioadhesion detachment force. The mucopenetration 
characteristics of nanoparticle were studied after oral administrations 
to rats by qualitative fluorescence of fluorescein isothiocyanate (FITC) 
labeled nanoparticles.
METHODS
Metronidazole and HPMCP HP55 grade were received ex gratia from 
La Pharma Pvt. Ltd. Ludhiana, Punjab, India. CS (85 deacetylated), 
Eudragit S100, Mono mPEG, Dialysis membrane (MW. 10-12 KDa) and 
FITC were procured from Sigma-Aldrich, USA. Trehalose dihydrate was 
obtained from Hi-Media Labs Pvt., Ltd., Mumbai. The other materials 
used were of analytical and pharmaceutical grades.
Preparation of CS nanoparticles
The nanoparticles were prepared with slight modification of 
method reported by [13] Makhlof et al., 2011. Briefly, polyelectrolyte 
complexation of positively charged CS with negatively charged 
enteric polymer HPMCP. In our preliminary investigations, polymer 
concentrations were optimized. For the preparation of nanoparticles, 
HPMCP (0.1%) solution in 0.1 M sodium hydroxide was slowly added 
to CS (0.1%) solution in 0.1 M acetic acid containing metronidazole 
under magnetic stirring for 30 minutes at 100 rpm. The pH of the final 
dispersion was kept 5.5. The nanoparticles produced were collected 
by centrifugation at 20,000 rpm (42,000 g) for 30 minutes at 4°C, and 
the supernatant was used for the measurement of free metronidazole. 
Collected nanoparticles were washed with double distilled water, freeze 
at −20°C in the deep freezer. Then freeze dried using D (+) trehalose 
dihydrate (0.5% w/v) as a cryoprotectant in lyophilizer (Martin Christ 
model Alpha 1-2 LD plus) at −55°C, 0.01 mm of Hg.
Synthesis of pegylated CS
Formaldehyde linking method was used to prepare copolymer of mPEG-
g-CS [14]. CS (85 deacetylated) (500 mg) was completely dissolved by 
continuous stirring in formic acid. Then, a suitable amount of mPEG 
(360 mg) was added. After 15 minutes, 1 ml of formaldehyde in formic 
acid solution and dimethyl sulfoxide was added to above mixture 
and solution was allowed to stir for 12 hrs. After that, the solution 
was dialyzed using dialysis tube (MW. 10-12 KDa) against an excess 
amount of double distilled water for 3 days. The dialyzed solution was 
lyophilized for 3 days, and the lyophilized product was precipitated in 
chloroform to remove the unreacted PEG. The precipitant was dried 
under vacuum to obtain the product and was stored at a temperature 
<4°C until further use.
Characterization of mPEG-g-CS copolymer
The mPEG-g-CS copolymer was characterized by Fourier transform 
infrared spectrophotometer (FTIR) (Thermo Nicolet-380, Thermo 
Scientific, U.S.A). The IR spectrum of mPEG-g-CS was recorded by 
placing the polymer sheet on pellet holder plate and scanning over a 
region of 400-4000 cm−1 (Table 1).
Preparation of mPEG-g-CS nanoparticles
The nanoparticles were prepared with slight modification of method 
reported by [13] Makhlof et al., 2011. Briefly, 0.1% w/v mPEG-g-
CS was dissolved in 1% w/v solution of acetic acid. HPMCP (0.1%) 
solution was prepared in 0.1 M sodium hydroxide. This solution was 
then slowly added to mPEG-g-CS solution containing metronidazole 
under magnetic stirring for 30 minutes at 100 rpm. The pH of final 




Morphology study of optimized formulations of nanoparticles was 
performed using scanning electron microscopy (SEM) (ZEISS EVO 
series SEM model EVO 50, Jeol, Japan). Sample was mounted on the 
sample holder and gold coating was done for microscopy.
Particle size, PDI, and zeta potential
Size distribution, PDI, and zeta potential of nanoparticles was 
determined using Zetasizer (Beckman Coulter, Delsa nano C). Samples 
were dispersed in double distilled water and were sonicated before 
estimation. All measurements were obtained in triplicate (n=3).
Percent drug entrapment
Nanoparticles obtained were digested with acetic acid (2%) solution 
using probe sonicator (Misonix, U.S.A.) for 20 minutes and centrifuged 
at 1000 rpm for 5 minutes. The supernatant was estimated for drug 
concentration using ultraviolet (UV) spectrophotometer (UV-1700-
Pharmaspec Shimadzu, Japan) at 277 nm. Drug entrapment (%) of 







In vitro release study
The release profile of metronidazole from CS and mPEG-g-CS 
polyelectrolyte complex nanoparticles were carried out in simulated 
gastric fluid and simulated colonic fluid (SCF) using dialysis membrane 
in Franz diffusion cell which was thermostatically maintained at 
37°C±1°C. Each release experiment was run in triplicate. Dialysis 
membrane (Sigma-Aldrich, USA) was used to separate receptor 
and donor compartments. The donor compartment containing 2 ml 
suspension of nanoparticles equivalent to 10 mg of metronidazole, 
mixed for 5 seconds to aid re-suspension, in a 1% w/v Tween 80 
solution in simulated gastric fluid/SCF [14]. Samples of 1 ml each were 
withdrawn from receptor compartment at different time intervals 
and replaced with fresh media in equal volume. Samples were diluted 
where necessary, filtered and analyzed spectrophotometrically at 
277 nm.
Table 1: IR spectrum peaks of CS-mPEG-g-CS
Peaks Chitosan Peaks mPEG-g-CS
2892 C-H stretch 2933 C-H stretch increased
1654 Amide I band, C-O stretch of acetyl group 1658 Amide I band, C-O stretch of acetyl group observed decrease
1577 Amide II band, N-H stretch 1592 Amide II band, C-O stretch of acetyl group observed decrease
IR: Infrared, CS-mPEG-g-CS: Chitosan-methoxy poly ethylene glycol-grafted-chitosan
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In vitro mucopenetration study
Collection and preparation of mucus sample
Freshly isolated pig intestinal ileum was taken from local slaughter 
house. It was kept in ice-cold oxygenated phosphate buffered saline 
(PBS) before sample processing. The colon part was taken and 
rinsed thoroughly with PBS. The mucus was then harvested through 
gentle scraping by spatula avoiding the shedding of epithelial tissue. 
Mucus was divided into aliquots (500 mg) and kept at −20°C before 
experimentation [15].
Mucopenetration study
The mucus (400 mg) was equilibrated at a constant temperature of 
37°C for 20 minutes in a vibrator to form homogenous dispersion of 
mucus. Then, it was placed in the donor chamber of Franz-diffusion 
cell with dialysis membrane located between donor and receptor 
compartment to support mucus. Then 2 ml of metronidazole loaded 
CS, and mPEG-g-CS nanoparticles were added to the surface of mucus. 
The receptor chamber was filled with PBS. After fixed interval of 
time 1ml of the sample was withdrawn and replaced with equal 
volume of PBS. The concentration of metronidazole was determined 
spectrophotometrically at 277 nm.
Synthesis of FITC conjugated CS polymer
FITC conjugated CS was synthesized using previously reported 
method [16]. CS was dissolved in 20 ml of 0.1 M acetic acid. It was kept 
overnight under stirring. Then 20 ml of methanol followed by 10 ml 
of FITC solution (2 mg/ml in methanol) were added to CS solution 
under continuous stirring. The reaction was allowed to proceed in dark 
room for 3 hrs. The FITC labeled CS was precipitated by adding 0.5 M 
sodium hydroxide till a pH of 8-9 was obtained. It was centrifuged at 
20,000 rpm for 10 minutes. The precipitate was washed thoroughly 
using deionized distilled water to remove free FITC. Then FITC labeled 
CS was then freeze dried.
Preparation of FITC labeled CS and mPEG-g-CS nanoparticles
FITC labeled CS and mPEG-g-CS nanoparticles were prepared and as 
described in previous section.
Bio-adhesion detachment force study
The bio-adhesive performance of 10 mg of CS and mPEG-g-CS 
nanoparticles was determined by measuring the force required to 
detach the formulation from the pig gastric mucosal tissue using 
modified [17] bio-adhesion detachment force measurement balance. 
The bio-adhesion detachment force (dyne/cm2) was calculated for 




Where m = weight in gram added to balance to detach the membrane.
g = acceleration due to gravity in m/s2.
A = area of the tissue exposed.
In vivo mucopenetration study
The in vivo mucopenetration studies were performed as per the regulation 
of Institutional Animal Ethical Committee of ISF College of Pharmacy, 
Moga, Punjab, India, vide protocol number IAEC/M17/311/2016, 
using FITC labeled CS and mPEG-g-CS nanoparticles. FITC labeled 
nanoparticles (10 mg/2 ml) were administered using oral feeding 
canula to two different groups of Wistar rats (n=12). After an interval 
of 5, 8, 12, and 24 hrs, three animals were sacrificed from each group, 
and colon portion from each animal was excised, washed with normal 
saline solution, and was fixed in 10% formalin, sectioned to a thickness 
of 10 µm and stained with eosin [18]. The fixed stained tissue sections 
were evaluated under digital microscope (×100) (Motic DMWB 
series) using Motic Images Plus 2.0 software and inverted fluorescent 
microscope (×40) (Olympus) to analyze the localization, mucoadhesion, 
and mucopenetration of fluorescent nanoparticles.
Stability studies
To evaluate the stability of metronidazole in the SCF, an aliquot of 10 mg 
of drug was dissolved in 50 ml of SCF and vibrated in a water bath 
maintained at 37°C. Subsequently, drug estimation was carried out at 2, 
8, 12, and 24 hrs time intervals respectively, to estimate the content of 
metronidazole to find out the percentage degradation of the drug in the 
gastrointestinal tract [18].
Statistical analysis
Results are presented as mean±standard deviation (SD). Wherever 
appropriate, differences between groups were evaluated with a Student 
t-test (two groups) at an alpha level of 0.05.
RESULTS AND DISCUSSIONS
The preparation of CS-HPMCP nanoparticles systems is based on 
an ionotropic gelation process, involving the interaction between 
positively charged amino groups of CS and negatively charged HPMCP 
to form CS-HPMCP polyelectrolyte nanoparticles, by the slow addition 
of anionic solutions. CS solution spontaneously changed from clear to 
the opalescent solution and finally to turbid suspension, indicating 
the formation of nanoparticles then microparticles and eventually 
aggregates. In a preliminary study, a pronounced increase in the particle 
size was observed by increasing CS concentration. Since the particle 
size is an important determinant of the biological efficacy of the drug-
loaded nanoparticles, the experimental conditions were adjusted for 
the preparation of nanoparticles in the size range of 200-300 nm with 
the highest process yield. Numbers of experiments were performed 
by varying the concentration of CS-HPMCP, to screen the appropriate 
concentration range so as to allow the formation of turbid solutions and 
not the aggregates. Stable and uniform nanoparticles in the size range of 
200-300 nm with positive surface charge and low polydispersity were 
produced at a CS concentration of 0.1% w/v coupled with 0.1% w/v 
HPMCP while maintaining the pH at 5.5.
Surface coating of nanoparticles with hydrophilic material like PEG 
leads to reduced hydrophobicity, improved stability in mucus and 
enhanced drug transport across the mucus. Pegylation offers several 
advantages to nanoparticles like less aggregation due to steric 
repulsion [19]. It results in large nanoparticles, enhanced drug loading 
and drug penetration due to less steric hindrance between mucus and 
the drug transport takes place without altering the mucus structure. 
Indeed pegylated nanoparticles have been shown to display high 
permeation through cervical–vaginal mucus [5] and within sputum 
from cystic fibrosis patients [20].
Synthesis and characterization of mPEG-g-CS
mPEG-g-CS was characterized by the FTIR spectroscopy. The IR spectrum 
of the CS and mPEG-g-CS is shown in Fig. 1 and was compared with the 
standard IR of mPEG-g-CS. The major peaks of CS and mPEG-g-CS were 
compared for the conformation of grafting as in The peak at 2933 cm−1 
due to C-H stretching was increased in grafted copolymer as compared 
to CS (2892.2 cm−1). Peaks at 1658 cm−1 and 1592 cm−1 can be attributed 
to amide I band and amide II band, respectively. The stretching of acetyl 
group (C-O), decreased due to attachment of mPEG on the amide amino 
group [21].
Characterization of nanoparticles
CS and mPEG-g-CS nanoparticles showed mean particle size 
distribution between the range of 200-300 nm (Fig. 2) which is suitable 
for uptake of nanoparticles in the inflamed colon [22]. CS and mPEG-
g-CS nanoparticles reasonably showed monodispersion with PDI <0.3 
(Table 2).
CS nanoparticles showed positive zeta potential of 26.94±2.4 mV, which 
is greater than mPEG-g-CS nanoparticles, i.e., 6.0±1.3 mV and is near to 
neutral. This may be due to the presence of PEG chains. Cationic charge 
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of CS thus prevents the interactions with mucin fibers. Both types of 
formulations showed very good entrapment efficiency. Comparatively, 
the particle size of mPEG-g-CS was more than CS nanoparticles thus 
entrapment efficiency was also better [23].
SEM of freeze dried CS, and mPEG-g-CS nanoparticles are shown in 
Fig. 3. The nanoparticles were seen as distinct spherical, consistent 
solid surface with porous structure. The observed matrix structure 
of nanoparticles was formed due to electrostatic force of attraction 
between anionic group of HPMCP and cationic group of CS [13].
Release studies
In vitro release studies were carried out on CS and mPEG-g-CS 
nanoparticles to evaluate the effect of pegylation. The dialysis 
method has been frequently reported for this purpose as it facilitates 
the separation of the released drug from the bound drug. However, 
the release rate of the drug is usually affected by the diffusional 
resistance of the membrane. In addition, sink conditions are difficult 
to be attained on the dialysis membrane resulting in a partition-
controlled release profile. In the current study, metronidazole 
release from the CS and mPEG-g-CS nanoparticles was evaluated 
in simulated gastric fluid (0.1M HCl solution) and SCF (pH 6.8). 
Metronidazole released from the CS nanoparticles in 2 hrs incubation 
period in 0.1 M HCl solution was 16.08±3.51% while in mPEG-g-CS 
nanoparticles was 13.23±3.2% (Fig. 4). After 2 hrs, there was a burst 
release of metronidazole due to the solubility of HPMCP in basic 
medium. When release profiles of CS and mPEG-g-CS nanoparticles 
were compared, pegylation led to enhanced drug release owing to 
increased hydrophilicity of nanoparticles by PEG. The solubility of CS 
in acidic medium is also reduced due to entanglement with HPMCP in 
polymeric matrix [12].
In vitro mucus mucopenetration study
The cumulative amount released from metronidazole loaded 
nanoparticles was 78% and 98% for CS and mPEG-g-CS, respectively. 
Comparing the two types of nanoparticles, there was enhanced release 
from mPEG-g-CS nanoparticles. This could be explained on the basis of 
enhanced solubility courtesy hydrophilicity of pegylated nanoparticles. 
The release study was conducted till 24 hrs.










Chitosan 202.7±27 0.213 26.94±2.4 79.8±5.4
mPEG-g-CS 294.1±46 0.268 6.0±1.3 83.6±9.7
mPEG-g-CS: Methoxy poly ethylene glycol-grafted-chitosan, PDI: Poly dispersity 
index
Fig. 2: Particle size and poly dispersity index of (a) chitosan and (b) methoxy poly (ethylene glycol)-grafted-chitosan nanoparticles
ba
Fig. 1: Infrared spectrum of (a) Chitosan (b) poly ethylene glycol-g-chitosan
a b
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Bio-adhesion detachment force study
The bioadhesion detachment force studies on nanoparticles (n=3) 
revealed the detachment stress was up to 14.98×103 dyne/cm2 for 
CS nanoparticles and it was 10.67×103 dyne/cm2 for mPEG-g-CS 
nanoparticles. The cationic amino groups present on the CS interact 
electrostatically with mucin glycoproteins, sialic acid, and other anionic 
moieties present on gastric mucosa [24]. The decrease in mucoadhesive 
capacity of mPEG-g-CS nanoparticles can be attributed to decrease 
in surface amino groups by ionic interaction [6]. This decline in 
bioadhesion can help the nanoparticles to infiltrate at a faster rate in 
gastric mucosa thus proving the utility of coated nanoparticles better 
for enhanced penetration and accumulation at the site of infection 
beneath mucosa.
In vivo mucopenetration study
The FITC labeled in vivo mucopenetration studies of CS nanoparticles in 
Wistar rats revealed localization and internalization, i.e., mucoadhesion 
and mucopenetration of good number of nanoparticles up to 8 hrs 
as shown in Fig. 5. The histopathology study of FITC labeled CS 
nanoparticles revealed that at in first 5 hrs nanoparticles got adhered 
to the colonic mucosa, but the penetration was visible only after 8 hrs. 
However, histopathological study of 24 hrs showed no fluorescence 
in the rat mucosa. Thus, the results reveal that the particles may be 
cleared with mucus as adhered and penetrated to the outer mucus layer. 
However, when the results were compared with FITC labeled mPEG-
g-CS nanoparticles, the internalization of the particles were more at 5 
and 8 hrs. This may be due to the reduction of surface charge which 
accelerates the adhesion and penetration of the nanoparticles into the 
mucus. A study conducted at 12 and 24 hrs showed good number of 
fluorescent particles in the inner mucus layer. This could be explained by 
taking surface charge into consideration irrespective of the particle size. 
There may be a less electrostatic interaction between mucin fiber with 
pegylated nanoparticles which accelerates the process of penetration 
into the outer mucus and then into the inner mucus, proximity to the 
epithelial cells [1]. Furthermore, particles were not cleared with mucus 
and remained at the site even after the mucus clearance. In addition 
to improving transport, pegylation may also enhance the stability 
of nanoparticles in mucus. Stability is particularly important when 
particles must diffuse through a thick mucus layer to reach underlying 
cells. There are remote chances that the rapid transport of pegylated 
particles is due to alterations of the mucus structure because they do 
not interact significantly with mucus. Instead, particles likely move in 
low-viscosity channels or pores within the mucus [6]. These results 
confirm the novel concept of mucopenetration by modifying the surface 
chemistry and shielding or decreasing the cationic charge on polymers 
like CS to increase the motility in mucosa [5,20]. Pegylation reduces the 
aggregation of the particles due to steric hindrance and protects the 
drug from degradation [19].
Stability of metronidazole in SCF
The percentage degradation of metronidazole in SCF was found to 
1.39±0.11% in 24 hrs suggested sufficient stability of the drug in SCF.
CONCLUSION
Poor mucus penetration of drug delivery system greatly reduces the 
therapeutic efficacy of medications used to treat mucosal infection. 
Proposed delivery strategies were introduced to enhance mucus 
penetration relying on physicochemical properties of nanoparticles. 
Studies inferred that physicochemical properties of drug carrier play 
an important role in determining the mucus penetration efficacy. 
Pegylation clearly enhanced the mucus penetration of nanoparticles, 
which is attributed to the change in surface properties particularly 
zeta potential, where particles with lesser zeta potential greatly 
reduce mucoadhesion and thus promotes muco-penetration. Studies 
thus provide evidence that planned pharmaceutical strategies 
Fig. 4: Cumulative percent release from chitosan methoxy poly 
(ethylene glycol)-grafted-chitosan nanoparticles
Fig. 5: Histopathological study of fluorescein isothiocyanate 
labeled chitosan and methoxy poly (ethylene glycol)-grafted-
chitosan
Fig. 3: Scanning electron microscopy of (a) chitosan and 
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open the window of opportunity for effective treatment of mucosal 
infections.
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